- Trials with a EudraCT protocol (2,288)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (5,797)
2,288 result(s) found for: CL.
Displaying page 1 of 115.
EudraCT Number: 2013-001556-35 | Sponsor Protocol Number: GENA-21 | Start Date*: 2013-07-26 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of individually tailored prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe hae... | |||||||||||||
Medical condition: Severe haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) SK (Completed) CZ (Completed) HU (Completed) BG (Completed) AT (Completed) ES (Prematurely Ended) DE (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002554-23 | Sponsor Protocol Number: GENA-05 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:OCTAPHARMA AG | |||||||||||||
Full Title: Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII in Previously Untreated Patients with Severe Haemophilia A | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) PL (Completed) DE (Completed) ES (Completed) FR (Completed) PT (Completed) SI (Completed) HR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011055-43 | Sponsor Protocol Number: GENA-08 | Start Date*: 2009-10-22 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study to Investigate the Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients With Severe Haemophilia A | |||||||||||||
Medical condition: Severe haemophilia A (FVIII:C <=1%) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021936-33 | Sponsor Protocol Number: RD.03.SPR.40131 | Start Date*: 2011-01-28 | |||||||||||
Sponsor Name:Galderma R&D SNC | |||||||||||||
Full Title: A multi-center randomized, double-blind, placebo controlled, parallel-group study of CD 07743 for the improvement of Lateral Canthal Lines (crow’s feet) | |||||||||||||
Medical condition: Moderate to severe Lateral Canthal Lines | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001563-11 | Sponsor Protocol Number: GENA-01 | Start Date*: 2009-10-22 |
Sponsor Name:Octapharma AG | ||
Full Title: Clinical Study to Investigate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of human-cl rhFVIII, a Newly Developed Human Cell-Line Derived Recombinant FVIII Concentrate in Previously Tr... | ||
Medical condition: Severe hemophilia A (FVIII:C <1%) | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male | |
Trial protocol: DE (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-003997-28 | Sponsor Protocol Number: GENA-15 | Start Date*: 2014-01-15 | |||||||||||
Sponsor Name:Octapharma Pharmazeutika Produktions GmbH, | |||||||||||||
Full Title: Extension Study for Patients who completed GENA-05 (NuProtect) – to Investigate Immunogenicity, Efficacy and Safety of Treatment with Human-cl rhFVIII | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) DE (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-004829-29 | Sponsor Protocol Number: 1222.6 | Start Date*: Information not available in EudraCT |
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | ||
Full Title: Randomised, double-blind, placebo-controlled, parallel group study to assess the efficacy (bronchodilation) and safety of 4 weeks of once daily treatment of orally inhaled BI 1744 CL (2 µg, 5 µg, 1... | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) FR (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-004828-36 | Sponsor Protocol Number: 1222.5 | Start Date*: 2007-02-08 | |||||||||||
Sponsor Name:Boehringer Ingelheim bv | |||||||||||||
Full Title: Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (2 µg, 5 µg, 10 µg, 20 µg) Deliv... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease (COPD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018644-14 | Sponsor Protocol Number: GENA-03 | Start Date*: 2010-11-16 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: PROSPECTIVE CLINICAL STUDY IN CHILDREN WITH SEVERE HAEMOPHILIA A TO INVESTIGATE CLINICAL EFFICACY, IMMUNOGENICITY, PHARMACOKINETICS, AND SAFETY OF HUMAN-CL RHFVIII | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023242-69 | Sponsor Protocol Number: GENA-11 | Start Date*: 2011-05-31 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study to Investigate the Long-Term Efficacy, Safety, and Immunogenicity of human-cl rhFVIII in Previously Treated Patients with Severe Haemophilia A – Extension Study to GENA-01 | |||||||||||||
Medical condition: Severe haemophilia A (FVIII:C <1%) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004891-20 | Sponsor Protocol Number: 1754-CLTF | Start Date*: 2021-03-09 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Study to determine the aetiology of chlormethine gel induced-skin drug reaction in early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL) | |||||||||||||
Medical condition: Early stage mycosis fungoides cutaneous T cell lymphoma (MF-CTCL) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Prematurely Ended) DE (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001785-17 | Sponsor Protocol Number: GENA-13 | Start Date*: 2011-09-27 | |||||||||||
Sponsor Name:Octapharma AG | |||||||||||||
Full Title: Clinical Study in Previously Treated Children with Severe Haemophilia A to Investigate the Long-Term Immunogenicity, Tolerability and Efficacy of Human-cl rhFVIII | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) FR (Completed) CZ (Completed) PL (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-001933-84 | Sponsor Protocol Number: 1222.13 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuat... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) DK (Completed) CZ (Completed) ES (Completed) IT (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002986-30 | Sponsor Protocol Number: GENA-21b | Start Date*: 2015-05-07 | |||||||||||
Sponsor Name:OCTAPHARMA AG | |||||||||||||
Full Title: Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A | |||||||||||||
Medical condition: Severe Haemophilia A | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) NL (Completed) FI (Completed) SI (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001976-39 | Sponsor Protocol Number: CHDR1227 | Start Date*: 2013-07-30 |
Sponsor Name:Centre for Human Drug Research | ||
Full Title: Randomized, open-label, crossover study into the contribution of the intestines and kidney in the diurnal variation of Levofloxacin pharmacokinetics | ||
Medical condition: The circadian variation in the relative contribution of intestinal uptake and renal elimination of levofloxacin | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-004587-23 | Sponsor Protocol Number: UZL/MBC SUBE0501 | Start Date*: 2005-12-23 |
Sponsor Name:UZ Leuven | ||
Full Title: A belgian multicenter phase II randomized trial in her2 negative metastatic breast cancer evaluating consolidation antiangiogenic therapy with SU11248 after response to taxane chemotherapy induction | ||
Medical condition: Patients must meet all of the following inclusion criteria in order to be eligible for participation in this study: • Patients with metastatic breast cancer, histologically proven • Patients receiv... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-004465-27 | Sponsor Protocol Number: COCA | Start Date*: 2018-02-01 |
Sponsor Name:Erasmus MC Cancer Institute | ||
Full Title: The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with colorectal cancer or other solid tumours ' the COCA s... | ||
Medical condition: Colorectal carcinoma or other solid tumours | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2016-003004-31 | Sponsor Protocol Number: NP25139 | Start Date*: 2016-08-09 |
Sponsor Name:F. Hoffmann-La Roche AG | ||
Full Title: An Open Label, Prospective, Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Intravenous Oseltamivir (Tamiflu) in the Treatment of Children 1 to 12 Years of Age With Influenza Infection | ||
Medical condition: Influenza | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2008-001934-28 | Sponsor Protocol Number: 1222.14 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Boehringer Ingelheim Finland Ky | |||||||||||||
Full Title: A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Study to Assess the Efficacy and Safety of 48 Weeks of Once Daily Treatment of Orally Inhaled BI 1744 CL (5 μg [2 actuat... | |||||||||||||
Medical condition: Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) CZ (Completed) DK (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001149-14 | Sponsor Protocol Number: A6181034 | Start Date*: 2004-09-27 | |||||||||||
Sponsor Name:PFIZER | |||||||||||||
Full Title: A Phase 3, Randomized Study of SU011248 versus Interferon-a as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma. | |||||||||||||
Medical condition: metastatic renal cell carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) ES (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
